Login to Your Account



Clinic Roundup


Monday, October 10, 2011
Dynavax Technologies Corp., of Berkeley, Calif., said results of a prospective analysis of the diabetic subset population from its Phase III trial (HBV-16) showed the superiority of Heplisav vs. Engerix-B (GlaxoSmithKline plc) at all measured time points.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription